Most oncogenes that have predominant roles in human cancer were first recognized in retroviruses. This includes the receptor tyrosine kinase epidermal growth factor receptor (EGFR), the small GTPase RAS, the phosphoinositide 3-kinase PI3K and the transcriptional regulator MYC. The discovery of retroviral oncogenes during the past four decades has set in motion an era of progress that has culminated in our current view of cancer as a genetic disease (TIMELINE) -a view that guides and inspires therapeutic innovations. It currently seems to be attractive to look back to the origins of the oncogene field, as they illustrate the first principles that are still valid and applicable to the legions of oncogenes encountered today.
There are slightly more than 30 retroviral oncogenes, which have been identified almost exclusively in avian and rodent viruses. Their products can be grouped into eight functional classes (TABLE 1) . The unifying functional assignment of these genes and proteins is signalling in the control of cellular replication. From this list, I discuss a few oncogenes that best illustrate the history of experimental and theoretical breakthroughs but that also have crucial roles in human disease.
The src paradigm The first retroviral oncogene to be discovered was src: this was no accident. Preparations of Rous sarcoma virus (RSV), the avian sarcoma virus that carries the src gene, induce readily visible oncogenic transformation within a few days in primary fibroblasts. RSV can be accurately titrated in cell culture, with a focus assay developed in 1958 (REF. 1) . In this assay, the focus number is directly proportional to the amount of virus, hence a single RSV particle can fully transform a host cell, and no cooperation between complementing viruses is required. Soon, methods for the biological cloning of RSV particles were developed, which were the fruit of extensive studies devoted to a replication-defective variant of RSV 2, 3 . A procedure for assaying non-oncogenic but actively replicating avian retroviruses by interference with RSV focus formation was also devised 4 . In the 1960s, these were powerful quantitative cell biological tools, and the avian sarcoma viruses were the only retroviruses for which such tools were available. This technological advantage was decisive in the discovery of the first oncogene.
Our knowledge of src and of its protein product is the culmination of a long and complex evolution with stepwise, successive contributions from genetics, biochemistry,
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Retroviral oncogenes: a historical primer Peter K. Vogt Abstract | Retroviruses are the original source of oncogenes. The discovery and characterization of these genes was made possible by the introduction of quantitative cell biological and molecular techniques for the study of tumour viruses. Key features of all retroviral oncogenes were first identified in src, the oncogene of Rous sarcoma virus. These include non-involvement in viral replication, coding for a single protein and cellular origin. The MYC, RAS and ERBB oncogenes quickly followed SRC, and these together with PI3K are now recognized as crucial driving forces in human cancer.
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immunology and structural biology 5 . Each of these steps built on and complemented the preceding one. Three early genetic observations helped to define the problem: first, there are mutants of RSV that, instead of transforming the fibroblast host into a rounded cell, induce an elongated fusiform cell shape 6, 7 . Therefore, the phenotype of the transformed cell is under the control of the viral genome. Second, a replication-defective variant of RSV transforms cells without producing infectious progeny, which indicated that the generation of progeny virus is not a prerequisite for oncogenicity 8, 9 . Third, most strains of RSV are non-defective 10, 11 (meaning that they carry all viral-replicative genes and the oncogene in the same RNA molecule) (FIG. 1) , but they spontaneously segregate deletion mutants that still replicate but can no longer transform cells 12, 13 . Reproduction and oncogenicity are separate and distinct functions.
The proof for the existence of a viral gene that initiates and maintains the transformed cellular phenotype came from experiments with temperature-sensitive mutants. In 1970, a groundbreaking paper in Nature described a mutant of the replication-competent Schmidt-Ruppin strain of RSV that transforms cells at a low, permissive temperature but that fails to transform cells at an elevated, nonpermissive temperature 14 . However, the production of progeny virus is unaffected by temperature. This mutant pointed to the existence of a viral gene that directs oncogenicity but that is dispensable for virus replication. An earlier report of temperature-sensitive mutants of RSV had also demonstrated this temperature dependence of transformation, but the temperature effect also extended to virus replication, probably owing to multiple mutations 15 . Biochemistry then provided the physical underpinning for the existence of a specific oncogene in RSV. This work depended on a unique property of the RSV genome: its non-defectiveness (as discussed above). All other oncogene-carrying retroviruses are replication defective, the oncogene having displaced one or several of the viral-replicative genes. Mutant RSVs that are transformation defective, but that are replication competent, contain a smaller RNA than the parental virus, suggesting that the lost sequences represent the oncogene 16 ( FIG. 1) . This hypothesis was supported by genetic mapping experiments. Temperaturesensitive mutations that affect the ability to transform cells were located to the region of the RSV genome that is deleted in the transformation-defective viruses 17 . Biochemical mapping with RNA fingerprinting showed that the deleted RNA was a contiguous fragment, located at the 3ʹ terminus of the viral RNA genome 18 . Thus, this was a piece of the retroviral genome that was not required for virus survival but that was essential for oncogenic transformation. The fact that this gene was readily lost from the viral genome showed that it did not convey an evolutionary advantage to the virus.
Where did this accessory piece of information come from? The biochemical experiments had defined a distinct nucleic acid segment of the retroviral RNA genome as the oncogene, and this definition then paved the way for the physical isolation of src. The discovery of reverse transcriptase in 1970 shifted the biochemistry of retroviruses from RNA to DNA, for which there existed better and more versatile tools of experimentation 19, 20 . One of these tools, subtractive hybridization, was applied to DNA transcripts of non-defective RSV and its replication-defective deletion mutant and so resulted in the isolation of src-specific DNA sequences. With these sequences it was possible to explore the origin of src, using hybridization as a measure of relatedness. These experiments showed that src originated from the cellular genome and that it was a cellular, not a viral, gene 21 . This fundamental insight, at first ridiculed, was soon extended to other retroviral oncogenes that had been discovered in the meantime, and it changed the landscape of tumour virology 22 . Retroviruses were no longer originators of oncogenic information: they were demoted to mere carriers of oncogenes that are part of the host genome. This discovery resulted in a huge expansion of the oncogene concept. Any cellular gene with an oncogenic potential that could be activated by a gain of function qualified as an oncogene. Most of these activating genetic events do not involve viruses, but retroviruses that lack an oncogene in their genome can still activate cellular oncogenes by insertional mutagenesis
.
The essential foundation for the genetics of src and of other retroviral oncogenes is the unique life cycle of retroviruses, which involves reverse transcription of the virion RNA into DNA, and the integration of this DNA into the host genome [23] [24] [25] . The genetic stability of the oncogenic phenotype induced by RSV had prompted Temin 26, 27 to propose the main elements of such a life cycle as the 'provirus hypothesis' . At the time, this seemed a preposterous idea because RNA-dependent synthesis of DNA overturned the central dogma of unidirectional flow of genetic information from DNA to RNA to protein. The sensitivity of retrovirus replication to inhibitors of DNA synthesis supported Temin's claim, but the evidence was far from compelling until the discovery of reverse transcriptase provided firm proof for the provirus hypothesis 19, 20 . Today, reverse transcriptase is used as a routine tool for copying genetic information, so it is important to remember that the generation of a double-stranded DNA copy from virion RNA and the integration of the provirus into the cellular genome are at the root of our understanding of retroviral oncogenes. Proviral integrations are genetic recombination events that can result in the incorporation of a cellular oncogene into the viral genome (FIG. 2) . Such acquisitions are rare; they can occur during viral passage in an animal but they are almost never seen in cell culture. There is no experimental system that predictably reproduces spontaneous oncogene acquisition; therefore, the molecular details of this process remain hypothetical 28, 29 . The data on the src gene had left an important question unanswered: what is the product of this oncogene? Considering the technical arsenal available at the time, it was not an easy question to answer. A phenomenal breakthrough was achieved in 1977 with a v-Src-specific antibody raised by a technique that was as ingenious as it was not obvious: injecting a mammalian-adapted RSV into young rabbits 30 . This antibody identified the v-src product as a 60 kDa protein that was soon found to have protein kinase activity 31, 32 . The crucial insight that differentiated the SRC kinase from other protein kinases known at the time came with the discovery of its target amino acid: it is not serine or threonine, but tyrosine 33 . The SRC protein was the first representative of this new class of tyrosine protein kinases, rapidly followed by EGFR 34 . Today, the members of this class are actively studied, and they have key regulatory functions in the cell 35 .
In the early 1980s, the cellular SRC and v-src genes were sequenced [36] [37] [38] [39] . The viral Src protein differs from its cellular progenitor by a carboxy-terminal deletion, which includes a crucial regulatory phosphorylation site, and by several point mutations. A comparison of the two proteins showed that the cellular SRC had a lower kinase and negligible oncogenic activity compared with viral Src [40] [41] [42] . The explanation of this difference evolved from the discovery that cellular SRC carries two modular protein-protein interaction domains, a phosphotyrosine-binding SH2 domain and a poly-proline-binding SH3 domain 43, 44 . Both are crucial for the regulation of SRC kinase activity. The molecular details of this regulation were revealed by the crystal structure of SRC and of the SRC family kinase HCK 45, 46 . Cellular SRC requires activation that opens the catalytic domain by disrupting intramolecular interactions involving both the SH2 and the SH3 domains. In viral Src, these inhibitory interactions are absent because of the C-terminal deletion and point mutations in the SH3 domain, making viral Src constitutively active.
The kinase activity of SRC invited a search for target proteins that would shed light on the normal and oncogenic functions of the enzyme. Multiple direct and indirect SRC targets have been identified, but the search for cancer-relevant functions is far from complete and remains an active area of cancer research 47 .
Discovering diversity
For the discovery and characterization of other retroviral oncogenes, some lessons from src could be transferred, but there were also new and unique challenges to overcome.
Other retroviruses that carry an oncogene are replication defective, in contrast to nondefective RSV. Replication-defective viruses require a helper virus that supplies the missing viral functions in trans. These viruses always occur as mixtures of transforming virus and non-transforming helper virus. Because of this dependence on a helper, the genetic experiments are less straightforward than with RSV. However, the structure of the genomes of replication-defective viruses can also offer an advantage: the displacement of viral-replicative genes by an oncogene can generate a fusion gene, combining cellderived and viral sequences, and resulting in the production of an oncogenic fusion protein. Such viral-cellular fusion products are readily identifiable with available viral antibodies.
A standard succession of events characterizes the history of most retroviral oncogenes. It starts with the identification of the gene in the virus. Here, two criteria that were first established for src have become signature traits of almost all retroviral oncogenes: cellular origin and non-identity with viralreplicative genes. Identification of the protein, cloning and sequencing are the next steps, and are extended to the cellular counter part of the gene. Questions of oncogenic and normal functions are then addressed, with such studies building on pre-existing knowledge of the cellular protein. In the early days of oncogene discovery, temperature-sensitive mutants had an important role. With the advances in cloning and sequencing, identifying such mutants became less important. The discovery of oncogenes in DNA viruses also started with temperature-sensitive mutants 31 . However, the genetic origins and molecular mechanisms of these oncogenes and oncoproteins stand in contrast to those of retroviruses. The crucial differences are summarized in BOX 2.
The potent trio in human cancer MYC. One of the first oncogenes that emerged after SRC was MYC. An RNA finger print analysis of the genome of the avian myelocytomatosis virus MC29 had revealed oligonucleotides that were unrelated to viral-replicative genes and to src 48 . The same sequences were also identified in the avian retroviruses CMII, OK10 and MH2 (REFS 49-51). The sequences were not scattered over the genome but were shown to form a contiguous stretch of RNA, indicating that they were derived from a distinct gene. A fusion protein combining viral Gag sequences of MC29 with the presumptive new oncoprotein was rapidly identified with viral antibodies 52 . DNA Figure 1 | The biochemical definition of v-src. The protein-coding regions of non-defective Rous sarcoma virus (RSV) encompass the complete information required for virus reproduction (gag, pol and env) and the information needed for oncogenic transformation (src). The RSV-infected cell produces progeny virus and is transformed. During the replication of RSV, mutant viruses are generated that are no longer oncogenic but that contain all the essential viral genes and are fully capable of producing progeny virus that fails to transform cells in culture. A comparison of the genome sizes of parental RSV and the transformation-defective mutant shows that loss of oncogenicity is correlated with loss of about 20% of the genome. The lost sequences represent the src gene, which is not essential for virus replication. Using DNA transcripts of these two viral genomes, src sequences can be purified by subtractive hybridization.
sequencing had just been invented 53, 54 , and within a few years it was applied to the viral myc and the human MYC genes 55, 56 . A first important insight into the functions of the MYC protein came with the discovery that it is localized in the cell nucleus 57 . One of the possible roles for this protein was to act as a transcriptional regulator. However, the failure of MYC to bind DNA under physio logical conditions could not be easily reconciled with this idea. This impasse was broken with the discovery of the MAX protein as an obligatory dimerization partner of cellular MYC. Only the MYC-MAX heterodimer can bind DNA with a high affinity and affect transcription 58 . MAX is the required partner of several MYC-related proteins, forming the central component of a regulatory network that can stimulate, as well as repress, transcription 59 . The workings of this network are based on selective dimerization. MAX forms DNAbinding homo dimers, but none of its partners has this ability, so they depend on dimerization with MAX to bind DNA and to regulate transcription.
The identification of MYC-target genes has been challenging because thousands of copies of its short DNA target sequence, the E-box CACGTG, are present in vertebrate genomes. A recent study using a combination of chromatin immunoprecipitation and deep sequencing identified more than 7,000 genomic-binding sites in a cell that overexpresses MYC 60 . Cellular levels of MYC are tightly regulated, and overexpression leads to uncontrolled cell replication or to apoptosis, depending on contextual factors that are not yet completely understood.
There are three MYC genes in the human genome: c-MYC (also known as MYC), MYCL1 and MYCN 55, 61, 62 . The cellular homologue of the retroviral myc gene is c-MYC. MYCN and MYCL1 were discovered later in human cells, and they have important roles in diverse human cancers 63 . The two representative mechanisms for the involvement of MYC in human disease came to light from studies of Burkitt's lymphoma and neuroblastoma. Burkitt's lymphoma cells always carry a chromosomal translocation that places c-MYC under the control of an immunoglobulin enhancer 64 . The result is increased transcription of c-MYC driven by the immunoglobulinregulatory sequences. The discovery of c-MYC rearrangements in a human lymphoma was the first indication that cellular counterparts of retroviral oncogenes are involved in the pathogenesis of human disease. In neuroblastoma, the MYCN gene is frequently amplified, and the expression of MYCN is correspondingly elevated 65 . Upregulated transcription and amplification are the two mechanisms for the oncogenic gain of function in the MYC genes. Mutations in the coding region of MYC do not have an important role in human cancer.
Recent studies indicate that the role of MYC in cancer goes beyond the situations in which it seems to be the primary driver. c-MYC has emerged as the mediator of resistance to inhibitors of PI3K, and dominant-negative MYC causes regression of RAS-induced tumours in mice 66, 67 .
RAS.
The isolation of v-ras presented a different set of challenges. The two principal viruses carrying this oncogene, Harvey sarcoma virus and Kirsten sarcoma virus, arose by recombination with the host genome during passage of murine leukaemia virus in rats 68, 69 . The rat-derived oncogene in these replicationdefective viruses is not fused to viral genes, and in the absence of such viral markers, the Ras protein could not be identified with viral antibodies. However, animals bearing Kirsten or Harvey sarcomas generated antibodies that interacted with the 21 kDa product of the ras gene 70 . The Ras protein was also obtained by in vitro translation of the viral genome 71 . Cloning and sequencing of the Harvey and Kirsten sarcoma viruses defined the viral and rat-derived contributions to these recombinant genomes and completed our molecular knowledge of the viral ras gene [72] [73] [74] . The two ras genes, Kirsten-ras (Ki-ras) and Harvey-ras (Ha-ras), do not differ in the properties we consider here.
A first clue about biochemical functions came from the observation that RAS has guanine nucleotide-binding activity, a finding that quickly culminated in the discovery that RAS is a GTPase [75] [76] [77] [78] . In its active form, RAS is bound to GTP, and binding could be enhanced by activated EGFR 79 . How could RAS be integrated into cellular signalling, and what was responsible for its oncogenic activity? Part of the answer came from linking an adaptor protein and a guanine nucleotide exchange factor to the activity of RAS 80, 81 . The SH2 domain of the adaptor, GRB2, binds to phosphorylated tyrosine, typically in a receptor tyrosine kinase (such as EGFR), and with its SH3 domain GRB2 can recruit the guanine nucleotide exchange factor (GEF) SOS. SOS stimulates the release of GDP from RAS and thus enhances loading with GTP. This sequence of interactions established the upstream signalling path that leads to RAS activation 82 . The other part of the answer, outlining the downstream activities of RAS, was initiated by the discovery of the raf oncogene in a murine sarcoma virus 83, 84 and of its avian homologue mil in the chicken tumour virus MH2 (REFS 85, 86) . The RAF protein binds to GTPloaded RAS and connects it to the MAPK pathway [87] [88] [89] . Activated RAS also binds to the catalytic subunit of PI3K, and this interaction is important for PI3K signalling 90 . Although numerous somatic mutations occur in the catalytic subunit of human PI3K, no mutations have been found in the RAS-binding domain, suggesting that interaction with RAS is essential for the function of PI3K. The oncogenic activities of PI3K are discussed in greater detail below.
The GTPase activity of RAS is stimulated by association with a GTPase-activating protein (GAP) 91 . RAS acquires oncogenic potency by point mutations affecting residues 12 and 61. These mutations disturb the interaction with GAPs. They reduce the rate of GTP hydrolysis and result in elevated levels of the active, GTP-bound Ras 78, [91] [92] [93] [94] [95] [96] . An important aspect of all RAS activity is cellular localization. RAS is positioned at the inner side of the plasma membrane, and this location is essential for its activity 97 . The interaction with membrane lipids is mediated by an obligatory post-translational isoprenylation of the protein 98, 99 . A series of exciting and dramatic experiments directly linked RAS to human cancer. Initially, the transfer of DNA from human cancer cells was found to transform recipient mouse cells. Integration of the source DNA into the genome of the recipient cells was verified by the presence of readily identifiable repetitive human sequences 100, 101 . This breakthrough came with the discovery that the transforming DNA that was derived from human cancer cells is homologous to ras [102] [103] [104] [105] . This discovery also linked a retroviral oncogene that in experimental systems induces
Box 1 | Activation of cellular oncogenes by insertional mutagenesis
Retroviruses of the subfamily oncovirus that lack an oncogene in their genome are able to induce cancer by insertional mutagenesis 178 . In this process, a provirus integrating in the vicinity of a cellular oncogene functions as a positive transcriptional regulator and thus activates the latent tumorigenic potential of the cellular gene. Insertional, retrovirus-mediated mutagenesis is a slow process that occurs only in the vertebrate host and that typically requires prolonged and extensive viral replication and integration. It has been widely used to reveal the oncogenic potential of cellular genes that are never transduced by viruses 179 . Nature Reviews | Cancer 22, [108] [109] [110] . For the induction of oncogenic growth, erbA is auxiliary but dispensable, whereas erbB is both necessary and sufficient, as a separate isolate of erythroblastosis virus, strain H, carries only the erbB oncogene but does not differ substantially from strain R in tumour spectrum or pathogenic potency 111 . Studies on additional independent isolates of avian erythroblastosis virus have supported this dominant role of erbB in oncogenesis 112 . Analyses of the cloned genomes and of in vitro translated proteins from strain R and H viruses suggested that the viral ErbB protein is produced by a fused mRNA consisting of a very short aminoterminal viral sequence and part of the cellular ERBB [113] [114] [115] [116] . In addition, specific antibodies detected a 74 kDa transformation-specific protein in cells infected by avian erythroblastosis virus 117, 118 . At the time, this information on chicken viruses seemed almost esoteric, but it has acquired great relevance for human disease. In a period of a few months in 1984, the viral ErbB protein was found to be glycosylated and phosphorylated, as well as structurally related to tyrosine kinases. It showed sequence features of tyrosine kinases and was localized as an integral membrane protein at the cell surface 115, [119] [120] [121] [122] [123] [124] [125] . Finally, and most importantly, sequence analysis revealed both close homology to cellular EGFR and a large deletion in the extracellular domain of viral ErbB 126, 127 . In addition to the N-terminal truncation, viral ErbB proteins show mutations in the kinase domain located in the C-terminal cytoplasmic portion of the protein. Viral ErbB functions as a constitutively active receptor tyrosine kinase; the activity is ligand-independent and also requires the kinase domain mutations. The mutations in viral ErbB do not merely cause a quantitative enhancement of the same signalling pathways that are controlled by cellular EGFR: they induce qualitative changes in the spectrum of signalling targets. These changes are crucial to the oncogenic potency of the protein 112 . EGFR can function as an oncogenic 'driver' in diverse human cancers. Mutations that mechanistically resemble those seen in viral ErbB occur in EGFR in glioblastoma and non-small-cell lung cancer. About 50% of glioblastomas carry the EGFRvIII mutant, which has lost a large portion of the extracellular domain and which no longer binds ligand but signals constitutively, addressing targets that are different from those of wild-type EGFR 128 . Such a cancer-specific mutation in a kinase would seem to be an ideal therapeutic target. However, the clinical experience with inhibitors of EGFR in glioblastoma has been uneven, with tumour shrinkage linked to the co-expression of EGFRvIII and the tumour suppressor PTEN 129 . In non-small-cell lung cancer, EGFR mutations are located in the kinase domain and lead to constitutive autophosphorylation and activation. Such cancers, seen mostly in non-smokers, are uniquely sensitive to EGFR inhibitors but regularly develop resistance to these drugs [130] [131] [132] [133] . The human genome contains three additional genes that are closely related to EGFR: HER2, HER3 and HER4 (also known as ERBB2, ERBB3 and ERBB4, respectively) [134] [135] [136] . The oncogenic potential of HER2 was discovered in transfection experiments with DNA from human neuroblastoma cells. The celltransforming gene in these experiments was identified as EGFR-related, with an activating mutation in the transmembrane domain 137 . HER2 is frequently amplified in breast cancer 138 . A humanized monoclonal antibody that inhibits HER2 signalling (trastuzumab) shows substantial clinical benefit and is now part of standard therapy for HER2 + breast cancers 139 . HER3 is unusual in that it has extremely low kinase activity and functions predominantly as a dimerization partner of other EGFR family members 140 . HER4 differs from the other EGFR-related genes in that it mediates cellular differentiation and inhibits replication 141 .
Oncogenes from slaughterhouse viruses
In the 1980s, it became clear that avian retroviruses are a particularly rich source of oncogenes. In chickens, retrovirus infection is common and widespread. Most of these viruses are replication-competent, do not carry an oncogene and induce tumours (mostly lymphoid leukosis) by insertional activation of a cellular oncogene 142 . But occasionally, the genetic recombination between Figure 2 | Acquisition of a cellular oncogene by a retroviral genome. First, virion RNA is transcribed into double-stranded DNA (RNA is shown in red and DNA is shown in green). Second, an accidentally truncated provirus is located upstream of a cellular gene (cellular exons are indicated in dark green; lighter colours represent viral sequences, and darker colours represent cellular sequences). Third, a spliced fusion transcript of viral and cellular sequences is packaged into a progeny virion together with a wild-type viral genome (retroviruses are diploid). Finally, during nextgeneration reverse transcription, recombination between the two genomes generates a DNA provirus composed of the cellular-oncogene-encoding sequence fused to viral sequences. As a result of acquiring cellular sequences, viral information that is essential for the production of progeny is lost, and such highly oncogenic viruses are replication defective, with the exception of most strains of Rous sarcoma virus (RSV), which can reproduce and are oncogenic. This mechanism for the acquisition of cellular sequences is hypothetical but in agreement with available experimental data.
virus and host can result in the incorporation of an oncogene into the viral genome. Such an acquisition converts the virus from slowly oncogenic to rapidly oncogenic, resulting in solid tumours that are distinct from endemic leukosis (FIG. 2) . Chicken slaughterhouses process up to 30,000 birds a day, and each of these chickens is inspected for signs of disease. At these numbers, even rare viral-cellular recombination events that result in aggressive cancers can be found.
Slaughterhouse veterinarians have greatly facilitated the discovery of several new, rapidly oncogenic retroviruses, and from these viruses, three new oncogenes were isolated: jun, qin and pi3k [143] [144] [145] . The discovery of the retroviral Jun, the finding of its cellular counterpart in the transcription factor complex activator protein 1 (AP1), and the identification of the tight partnership with the oncoprotein Fos (discovered separately in the Finkel-Biskis-Jinkins murine sarcoma virus 146 ), marked an exciting period in the history of oncogenes. The story of these events has been told elsewhere 147, 148 . QIN (also known as FOXG1) is a representative of the winged helix or FOX family of DNA-binding proteins that function as developmental and metabolic transcriptional regulators 144 . Although QIN has not been implicated in human cancer, the FOX protein family is linked to human disease by the involvement of FOXO1 in a chromosomal translocation that contributes to the development of alveolar rhabdomyosarcoma, which is an aggressive childhood tumour. Another member of the family, FOXA1, controls the sexual dimorphism seen with hepatocellular carcinoma 149 . A broader survey of the association of FOX proteins with cancer has been presented in a recent review 150 . Among the oncogenes derived from these recently isolated avian retroviruses, pi3k stands out because its cellular counterpart controls signalling pathways that show aberrant activation in most human tumours and also contain promising drug targets. Retroviral pi3k has served as an important model for the oncogenic activities of human PI3K. There has long been a suspicion that the lipid kinase PI3K may have oncogenic potential. In early work, the oncoproteins of DNA viruses, as well as Src, were shown to be associated with a cellular lipid kinase activity [151] [152] [153] [154] [155] . This interaction was essential for the oncogenicity of these viral proteins. The transformation-associated lipid kinase activity was then found to catalyse the phosphorylation of the D3 position of the inositol ring, defining a novel enzymatic activity that generates phosphatidylinositol-3-phosphates 156 . The fundamental importance of this finding was not realized until much later when it became clear that this PI3K was at the centre of an extensive and versatile cellular signalling network that becomes corrupted in most cancers 157, 158 . Direct evidence for the oncogenicity of PI3K came with the discovery of an avian haemangiosarcoma virus, ASV16, in a tumour obtained from a chicken-processing plant. ASV16 is a replication-defective virus with a genome that encodes a single protein encompassing the p110α isoform of the catalytic subunit of chicken PI3K fused N-terminally to viral gag sequences 145 . Viral pi3k harbours several mutations in the p110α-coding sequence, but these do not induce a gain of function and are irrelevant for oncogenic activity. Oncogenicity depends on the N-terminal Gag sequences 159 . The Gag sequences were initially thought to facilitate membrane localization and bring the enzyme in direct contact with its substrate. Support for this idea comes from the observation that a myristylation signal added to the N terminus of cellular p110α also has a strongly activating effect and makes the protein oncogenic. However, recent data have cast doubt on this interpretation. Even random amino acid sequences, added to the N terminus of p110α, are activating, and there is no requirement for a membranelocalizing function in these sequences. Rather, these N-terminal additions seem to induce a conformational change that mimics the activation of p110α by upstream signals 160 . A similar mechanism for constitutive activity is seen with cancer-specific mutations that carry an amino acid substitution in the helical domain of p110α [161] [162] [163] [164] . In such mutants, the inhibitory interaction with the regulatory subunit p85 is disrupted.
PI3K has moved into the limelight as a cancer target because of frequent cancerspecific genetic and epigenetic changes that result in enhanced activity. These include loss-of-function mutations in the PI3K antagonist and tumour suppressor PTEN, increased activity and amplification of PI3K, and gain-of-function mutations in the catalytic subunit p110α [165] [166] [167] [168] [169] [170] . Enhanced PI3K signalling is a driving force in cancer develop ment. Academic laboratories and the pharmaceutical industry have responded to this situation by generating small-molecule inhibitors of PI3K, and several of these are currently in advanced clinical trials 171 .
From simplicity to complexity
As we look at the history of oncogenes and their importance in human disease, two developmental trends unfold (TIMELINE). One is a steady increase in relevance, the other a broadening of the concept of cancer as a genetic disease. Rapidly tumorigenic retroviruses that carry oncogenes have mostly been found in chickens and in mice. Early work with these viruses focused on cancer as an infectious condition. But the concepts and mechanisms uncovered with readily transmissible animal tumours did not seem to be applicable to the human situation. Therefore, the importance of identifying specific oncogenes in viruses was at first exclusively experimental and theoretical. These discoveries showed that normal vertebrate cells could be transformed into cancer cells by the action of a single gene. This was a revolutionary insight, offering simplicity and the prospect of complete molecular understanding.
Retroviral oncogenes remained mainly experimental tools with uncertain ties to human cancer until 1976, when oncogene sequences were found in cellular genomes 21 . This discovery transformed the field. Retroviruses, with their ability to acquire and transduce host genes, became just one of several possible ways by which a cellular oncogene can be activated. In principle, any genetic change in the cellular oncogene is Box 2 | Contrasting mechanisms in viral oncogenicity: RNA versus DNA viruses
The oncogenes of retroviruses are cell-derived; they deregulate cellular signalling and transcriptional controls. By contrast, oncogenic DNA viruses, including the papilloma viruses, polyoma virus, simian virus 40 (SV40) and some tumour-inducing adenoviruses and herpesviruses, carry their own oncogenes. Some of the best understood among these disrupt the RB protein-mediated control of the cell cycle [180] [181] [182] [183] [184] . During the G1 phase of the cell cycle, the RB protein is hypophosphorylated and bound to E2F transcription factors, forming transcriptional repressor complexes. These are essential components of the restriction point that prevents entry into the S phase of the cell cycle. On mitogenic stimulation, cyclin-dependent kinases phosphorylate RB, thus releasing the E2F proteins, which then initiate a transcriptional programme that marks the entry into the S phase. Several DNA viral proteins bind to hypophosphorylated RB: the E1A protein of adenoviruses, the large T antigen of SV40 virus and the E7 proteins of oncogenic human papilloma viruses. These interactions free the E2F proteins without a requirement for mitogenic signals and start the S phase of the cell cycle. Proteins of oncogenic DNA viruses can also operate as constitutive signalling receptors or can interfere with the functions of inhibitors of cyclin-dependent kinases 185 .
potentially activating. The next transformative step on the way to relevance established the direct connection between the cellular versions of retroviral oncogenes and human cancer. The key breakthroughs were finding transcriptional activation of c-MYC by chromosomal translocation in Burkitt's lymphoma, detecting amplification of MYCN in neuroblastoma and identifying activated RAS in DNA from human cancer cells 64, 65, [102] [103] [104] . These and other human cancer-driving retroviral oncogenes are listed in TABLE 2.These findings were fundamental in revealing cancer as a genetic disease. They also seemed to be a reductionist triumph, explaining cancer with changes in one, or at the most a few, genes that would generate novel and highly specific therapeutic targets.
This development took retroviral oncogenes from obscurity to prominence, but in subsequent years, genetic changes that affect the oncogenic cellular phenotype have steadily increased in type and in number. If we define an oncogene as a replication-promoting gene that encodes a protein and shows gain of function in cancer, then the number of such genes is probably in excess of 1,000 and growing. A comprehensive view of cell-autonomous genetic alterations in cancer further includes tumour suppressors that contribute to the oncogenic phenotype by a loss of function, often as a result of epigenetic changes 172 . MicroRNAs have added another layer of complexity, with both pro-oncogenic and anti-oncogenic effects 173 . The vast extent of the non-coding transcriptome, including large antisense transcripts and pseudogenes, is beginning to be functionally explored and probably holds even more surprises 174 . Cancer genome projects have uncovered an unexpected multitude of genetic changes in all cancers, revealing mutational landscapes that are characteristic of tumour origin and histology. A similar trend towards complexity can be seen in our understanding of oncoprotein functions. All these proteins show multiple activities, generating diverse signals. A complete molecular understanding of how these activities initiate and maintain cancer remains a challenge.
The complexity of genetic alterations becomes irrelevant in certain cancers that show a striking and apparently irreversible dependency on a single, dominant genetic change. Such oncogene addiction can be the basis for stunning clinical successes with targeted therapy 175 . However, it is questionable whether the model of cellular addiction to a single oncoprotein is applicable to a broad range of cancers. In the more common scenario, complexity rules and dictates a therapeutic strategy that relies on targeting a few crucial drivers of the oncogenic cellular phenotype. Success depends on the identification and validation of these drivers as cancer targets 176, 177 . These efforts are guided by the general principle that it is easier to correct a gain of function than to restore a loss of function. Oncogenes remain very much in the line of fire. 
